The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data

We reviewed the bibliography of prior meta-analyses, review articles, and studies that underwent full-text screening for additional studies to maximize the yield

N. Alammar; L. Wang; B. Saberi; J. Nanavati; G. Holtmann; R. T. Shinohara; G. E. Mullin

2019

Scholarcy highlights

  • Peppermint oil has intrinsic properties that may benefit patients with irritable bowel syndrome symptoms
  • A total of 427 studies remained for a review of titles and abstracts, from which 22 trials were identified that underwent full text screening
  • Lech et al failed to utilize any validated inclusion criteria, though they did find a significant benefit for PO relative to placebo for improvements in abdominal pain
  • Liu et al failed to utilize any validated inclusion criteria, though they did find a significant benefit for PO relative to placebo for the improvement of abdominal pain
  • The risk ratio for seven randomized controlled trials for the effect of PO versus placebo on global symptoms was 2.39, I2 = 0%, z = 7.93
  • There was no statistically significant difference in reported adverse effects in IBS subjects using PO versus placebo; RR 1.40, I2 = 0%, z = 1.39
  • Five studies for data that was shown in other publications, four RCTs were cross-over trials without sufficient washout period, and an RCT was permitted rescue medication without sufficient data to permit analysis.

Need more features? Save interactive summary cards to your Scholarcy Library.